Stereotaxis (STXS) Stock Price, News & Analysis

Company Overview

Stereotaxis, Inc. is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia. In addition to the Niobe platform, Stereotaxis has introduced the Vdrive Robotic™ system and the EPOCH® solution, which further automate catheter control and sheath deflection to streamline workflow in the electrophysiology lab. Stereotaxis also offers training, installation and technical support services to help facilities adopt and optimize use of its robotic navigation technology.

Founded in 1997 and headquartered in St. Louis, Missouri, Stereotaxis has installed systems at leading hospitals and cardiac centers across North America, Europe, the Middle East and Asia-Pacific. The company maintains strategic collaborations with key electrophysiology mapping and imaging partners to advance integration and clinical data collection. Stereotaxis is led by President and Chief Executive Officer Jim Corriveau, whose team brings extensive experience in medical device innovation, regulatory affairs and global product commercialization.

Key Stats

• Today's Range: $1.35 to $1.40
• 50-Day Range: $1.26 to $1.89
• 52-Week Range: $1.24 to $3.59
• Volume: 535,117 shs
• Average Volume: 947,246 shs
• Market Capitalization: $133.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.70
• Consensus Rating: Buy

Stereotaxis Stock Analysis - MarketRank™

Stereotaxis scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Stereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Stereotaxis has a consensus price target of $3.70, representing about 172.1% upside from its current price of $1.36.

Amount of Analyst Coverage

Stereotaxis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stereotaxis are expected to grow in the coming year, from ($0.22) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stereotaxis is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stereotaxis is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stereotaxis has a P/B Ratio of 9.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.45% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 2.47, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Stereotaxis has recently increased by 0.54%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stereotaxis does not currently pay a dividend.

Dividend Growth

Stereotaxis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.19

News Sentiment

Stereotaxis has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Stereotaxis this week, compared to 1 article on an average week.

Search Interest

11 people have searched for STXS on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

MarketBeat Follows

7 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Stereotaxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.03% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/18/2026
• Investor presentation: 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSEAMERICAN:STXS
• CIK: 1289340
• Web: www.stereotaxis.com
• Phone: (314) 678-6100
• Fax: 314-678-6159
• Employees: 130
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Stereotaxis: $3.70
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +172.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.64 million
• Net Margins: -74.24%
• Pretax Margin: -74.24%
• Return on Equity: -130.84%
• Return on Assets: -29.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.42
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $32.38 million
• Price / Sales: 4.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 9.71

Miscellaneous

• Outstanding Shares: 97,930,000
• Free Float: 82,235,000
• Market Cap: $133.18 million
• Optionable: Not Optionable
• Beta: 1.37